RemeGen, Ltd. Announces Positive Results from Phase IIb Clinical Trial in Systemic Lupus Erythematosus
BioTech Gate,
YANTAI, China, Nov. 15, 2019 /PRNewswire/ -- RemeGen, Ltd. today announced a Phase IIb clinical trial of RC18 (telitacicept), a…
YANTAI, China, Nov. 15, 2019 /PRNewswire/ -- RemeGen, Ltd. today announced a Phase IIb clinical trial of RC18 (telitacicept), a…
YANTAI, China, Nov. 15, 2019 /PRNewswire/ -- RemeGen, Ltd. today announced a Phase IIb clinical trial of RC18 (telitacicept), a…
SOURCE RemeGen, Ltd. RC18 (telitacicept) demonstrated statistically significant improvement in systemic lupus erythematosus (SLE…
SOURCE RemeGen, Ltd. RC18 (telitacicept) demonstrated statistically significant improvement in systemic lupus erythematosus (SLE…